Health
Johnson & Johnson’s Coronavirus Vaccine Candidate Efficacious in Pre-Clinical Studies; Human Testing Has Begun – The Motley Fool
The company aims to start a phase 3 clinical trial for Ad26.COV2-S in September.
Johnson & Johnson(NYSE:JNJ) has gained some ground in the coronavirus vaccine race. On Thursday, the pharmaceutical and consumer goods company announced that in pre-clinical studies, its Ad26.COV2-S vaccine candidate had demonstrated effectiveness in protecting on non-human primates from infection with SARS-CoV-2.
In contrast to other coronavirus vaccine candidates — such as the one many observers view as the most promising, Moderna’s mRNA-1273 — Johnson & Johnson’s produced its respo…
-
General22 hours agoDonald Trump’s initial 10 per cent tariff takes effect
-
General21 hours agoJaguar Land Rover in UK pauses shipments to US
-
General18 hours agoTexas opens probe into Kellogg’s health claims, dyes
-
General17 hours agoAustralian share market set to dive as threat of US recession grows